Amicogen and Lysando: Novel approach for the treatment of mastitis in dairy cows
more
Stories about Biotechnologie
Björn Cochlovius New CEO of Eleva / Seasoned Molecular Biologist and Entrepreneur Leads German Biotech Company into its Next Development
Freiburg, Germany (ots) - Björn Cochlovius Ph.D. has become the new CEO of Eleva, a Freiburg-based biotech company and the developer of “Bryotechnology”, a unique and pioneering process for the moss-based production of complex therapeutic proteins. The renowned oncologist, immunologist, and molecular biologist ...
moreDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
moreMiltenyi Biotec acquires biosensor company lino Biotech
Zurich (ots) - lino Biotech, a leading biosensor company and the world’s only provider of Focal Molography, announced today it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023. Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy ...
moreBlood Donation Day at R-Biopharm: Employees Help Save Lives
morebiomindz Standortentwicklungsgesellschaft Mainz GmbH i.G.
Newly established company to promote Mainz as hub for life science and biotechnology now operational and supporting the city of Mainz
moreCO.DON finally saved - investor has taken over the business operations of the Leipzig-based biopharmacy company with an additional location in Teltow, Brandenburg
Leipzig / Teltow (ots) - CO.DON continues business operations as a GmbH (limited liability company) With effect from 20.01.2023, CO.DON's business activities will be continued in the legal form of a GmbH (limited liability company) following a transferring reorganisation. The asset deal with Rejuvenate GmbH, a ...
moreDEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
Lausanne, Switzerland (ots) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel ...
moreMars Petcare and the Broad Institute create open-access database of dog and cat genomes to advance preventive pet care
New York (ots/PRNewswire) - - The genome database will power ongoing scientific efforts worldwide and help advance individualized pet health care - Insights from this partnership will feed into the MARS PETCARE BIOBANK™, a longitudinal study to understand pet health and disease, transforming pet care for future ...
moreFlu tests from R-Biopharm also detect new virus variants
moreStem cell therapy for “Butterfly disease” / RHEACELL receives ‘Partners in Progress Award’ from debra of America for Epidermolysis Bullosa research
moreR-Biopharm starts commercialization of the fully automated RIDA®UNITY system for real-time PCR in molecular diagnostic laboratories
moreLeukocare announces new management structure to support global set-up and accelerate growth
Martinsried/Munich (ots) - Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, today announced the introduction of a new management structure, effective July 1st, 2022, designed to support the global organizational set-up and to further accelerate the company’s growth. The newly established Executive Board ...
moreR-Biopharm is IVDR certified
more- 2
R-Biopharm acquires Australian lab equipment manufacturer and molecular biology multiplex specialist AusDiagnostics
more R-Biopharm announces test to detect monkeypox virus
moreUniversity of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients
Baltimore, MD (ots) - Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer.” “The ability to reliably detect HPV-DNA ...
moreThe New Era Biotechnology Co., Ltd.
The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)
moreAlmirall delivers solid nine months 2021 results and tightens its upgraded guidance
Barcelona, Spain (ots/PRNewswire) - - Strong Core business performance with growth in Core Net Sales EUR601.7 MM (+6.2% year-on-year) and Core EBITDA reaching EUR164.2 MM, (+20.3% year-on-year) driven by positive contribution from Growth Drivers and a strong EU dermatology performance - Key Growth Drivers underpinning increase in Core Net Sales. Strong performance from ...
moreDr. Dirk Winnemöller joins Leukocare as Vice President Commercial
Martinsried/Munich (ots) - Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, today announced that Dr. Dirk Winnemöller took up the newly established role as Vice President Commercial at Leukocare. Dirk joins the Company from Miltenyi Biomedicine GmbH, Bergisch Gladbach, Germany, where he served as Global Vice ...
moreAlmirall S.A.: Experts highlight the need to focus on psoriasis patients' wellbeing in clinical practice
Barcelona, Spain (ots/PRNewswire) - - Psoriasis affects the overall emotional wellbeing of 88% of patients[1], and at least 20% of psoriasis patients have considered suicide[2] - Currently used endpoints in psoriasis do not capture the full impact of this skin condition on patients' lives, and almost 50% of them ...
moreEleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases. Eleva has ordered four more state-of-the-art, 500 l single-use reactors from Sartorius Stedim Systems. The scale-up will enable Eleva to enter ...
moreLebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic deramatitis in two Phase 3 trials
Barcelona (ots/PRNewswire) - - Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials - Safety profile consistent with prior lebrikizumab studies in atopic dermatitis Lebrikizumab led to significant improvements with ...
moreSysmex Inostics presents data at ASCO
Baltimore, MD (ots) - Sysmex Inostics presents data at ASCO showing HPV-SEQ, a new CLIA-validated SafeSEQ NGS HPV16/18 liquid biopsy assay, is highly effective for measuring HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial. Sysmex Inostics, Inc., a global leader in the liquid biopsy revolution for oncology, is presenting the poster ...
moreEleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member
Freiburg (ots) - Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to ...
moreEvoBiotiX collaborates with Boehringer Ingelheim and the University of Salzburg on naturally derived Extracellular Vesicles (EVs)
Salzburg/Melide(CH) (ots) - Swiss Biotech EvoBiotiX SA today announced a multi-year collaboration with Boehringer Ingelheim in the field of naturally derived EVs. A significant part of this program will fund research of the drug delivery potential of naturally derived EVs in the group of Prof. Meisner-Kober at the ...
moreRegulatory breakthrough for BrainRepair UG start-up - Stem cell treatment for newborns /EMA Orphan Drug Designation is followed by agreement on Paediatric Investigation Plan
moreVersameb raises CHF 6 million and strengthens team to advance its VERSagile technology platform towards clinical trials
Basel, Switzerland (ots) - Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective ...
moreIgNova files patent application on antibody against COVID-19
Visbek, Germany (ots) - IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (IgY). The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the ...
moreElastrin Therapeutics develops new approach against "Inflammatory Storm" that kills most Corona patients
Greenville South Carolina (ots) - A previously untested approach to preventing the most severe outcomes of lung diseases, including COVID-19, has been developed by Elastrin Therapeutics based on targeting damaged elastic fiber that leads to impaired lung function. The company has developed the world's first ...
more
Previous123Next